109 related articles for article (PubMed ID: 23623928)
21. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
22. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
[TBL] [Abstract][Full Text] [Related]
23. Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma.
Michalek J; Ocadlikova D; Matejkova E; Foltankova V; Dudová S; Slaby O; Horvath R; Pour L; Hajek R
Br J Haematol; 2010 Mar; 148(6):859-67. PubMed ID: 20067568
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunoediting and immune dysregulation in multiple myeloma.
Nakamura K; Smyth MJ; Martinet L
Blood; 2020 Dec; 136(24):2731-2740. PubMed ID: 32645135
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
26. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
27. Virus-based immunotherapy of cancer: what do we know and where are we going?
Sørensen MR; Thomsen AR
APMIS; 2007 Nov; 115(11):1177-93. PubMed ID: 18092950
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for multiple myeloma: Current status and future directions.
Ayed AO; Chang LJ; Moreb JS
Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
31. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
32. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
33. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
Chiriva-Internati M; Cobos E; Kast WM
Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccination against multiple myeloma.
Stevenson FK; Link CJ; Traynor A; Yu H; Corr M
Semin Hematol; 1999 Jan; 36(1 Suppl 3):38-42. PubMed ID: 9989489
[TBL] [Abstract][Full Text] [Related]
35. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppression and infection in multiple myeloma.
Jacobson DR; Zolla-Pazner S
Semin Oncol; 1986 Sep; 13(3):282-90. PubMed ID: 3532328
[TBL] [Abstract][Full Text] [Related]
37. Cellular Immunotherapy for Multiple Myeloma.
Rosenblatt J; Avigan D
Cancer J; 2019; 25(1):38-44. PubMed ID: 30694858
[TBL] [Abstract][Full Text] [Related]
38. Immunogenic therapy: new actors in myeloma.
Solimando AG; Vacca A
Blood; 2024 Jun; 143(25):2564-2565. PubMed ID: 38900472
[No Abstract] [Full Text] [Related]
39. Update on Resistance Mechanisms and Therapeutic Strategies in Multiple Myeloma. Proceedings of the 5th workshop of the Cooperative Study Group Cellular Resistance. Wurzburg, Germany, 21-22 November.
Leukemia; 1997 Dec; 11 Suppl 5():S1-58. PubMed ID: 9463132
[No Abstract] [Full Text] [Related]
40. Osteoporosis and immunosuppression in multiple myeloma.
Farrell AM; Powell RJ
BMJ; 1989 Nov; 299(6708):1164. PubMed ID: 2513038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
